{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:18:02Z","timestamp":1787642282001,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04246-5","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T08:02:49Z","timestamp":1753344169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early relapse during B lymphocyte depletion of children with frequently relapse \/steroid dependent nephrotic syndrome after rituximab treatment"],"prefix":"10.1186","volume":"26","author":[{"given":"Juan","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huarong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"4246_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392:61\u201374.","journal-title":"Lancet"},{"key":"4246_CR2","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/archdischild-2020-321211","volume":"106","author":"R Sinha","year":"2021","unstructured":"Sinha R, Agrawal N, Xue Y, Chanchlani R, Pradhan S, Raina R, et al. Use of rituximab in paediatric nephrology. Arch Dis Child. 2021;106:1058\u201365.","journal-title":"Arch Dis Child"},{"key":"4246_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY Chan","year":"2020","unstructured":"Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, et al. Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int. 2020;97:393\u2013401.","journal-title":"Kidney Int"},{"key":"4246_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023;38:877\u2013919.","journal-title":"Pediatr Nephrol"},{"key":"4246_CR5","unstructured":"Immunity Evaluation Group, China Children\u2032s Immunity and Health Alliance; Rheumatology and Immunology Committee, Chinese Medical Doctor Association Pediatrician Branch; Children Allergy Committee, Chinese Medical Doctor Association Pediatrician Branch. Consensus on analysis of peripheral blood lymphocyte subsets by flow cytometry in pediatric clinical application (2019). Zhonghua Er Ke Za Zhi. 2019; 2;57(6):424\u2013428."},{"key":"4246_CR6","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1007\/s00467-021-05048-1","volume":"36","author":"S Sheikh","year":"2021","unstructured":"Sheikh S, Mishra K, Kumar M. Low-dose versus conventional-dose prednisolone for nephrotic syndrome relapses: a randomized controlled non-inferiority trial. Pediatr Nephrol. 2021;36:3143\u201350.","journal-title":"Pediatr Nephrol"},{"key":"4246_CR7","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, D\u00f6tsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 2004;19:794\u20137.","journal-title":"Pediatr Nephrol"},{"key":"4246_CR8","doi-asserted-by":"publisher","unstructured":"Gao X, Wang Y, Xu Z, Deng H, Yang H, Zhong F et al. Systematic review and meta-analysis of rituximab for steroid-dependent or frequently relapsing nephrotic syndrome in children. Front Pediatr (2021 Jul) https:\/\/doi.org\/10.3389\/fped.2021.626323","DOI":"10.3389\/fped.2021.626323"},{"key":"4246_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1136\/archdischild-2019-318019","volume":"106","author":"R Sinha","year":"2021","unstructured":"Sinha R, Banerjee S, Mukherjee A, Akhtar S, Pradhan S. Impact of rituximab on anthropometric indices among childhood steroid-dependent nephrotic syndromes. Arch Dis Child. 2021;106:283\u20135.","journal-title":"Arch Dis Child"},{"key":"4246_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013157","author":"YH Ahn","year":"2018","unstructured":"Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, et al. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea. Med (Baltim). 2018. https:\/\/doi.org\/10.1097\/MD.0000000000013157.","journal-title":"Med (Baltim)"},{"key":"4246_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10157-016-1328-y","volume":"21","author":"S Fujinaga","year":"2017","unstructured":"Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, et al. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. Clin Exp Nephrol. 2017;21:671\u20136.","journal-title":"Clin Exp Nephrol"},{"key":"4246_CR12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. Rituximab for Childhood-onset refractory nephrotic syndrome (RCRNS) study group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273\u201381.","journal-title":"Lancet"},{"key":"4246_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, et al. Efficacy of rituximab vs tacrolimus in pediatric Corticosteroid-Dependent nephrotic syndrome: A randomized clinical trial. JAMA Pediatr. 2018;172:757\u201364.","journal-title":"JAMA Pediatr"},{"key":"4246_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00467-018-4063-7","volume":"34","author":"T Takahashi","year":"2019","unstructured":"Takahashi T, Okamoto T, Sato Y, Yamazaki T, Hayashi A, Aoyagi H, et al. Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study. Pediatr Nephrol. 2019;34:87\u201396.","journal-title":"Pediatr Nephrol"},{"key":"4246_CR15","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00467-020-04609-0","volume":"36","author":"EY Chan","year":"2021","unstructured":"Chan EY, Tullus K. Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen. Pediatr Nephrol. 2021;36:1397\u2013405.","journal-title":"Pediatr Nephrol"},{"key":"4246_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaut.2017.10.006","volume":"88","author":"A Boumediene","year":"2018","unstructured":"Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, et al. NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome. J Autoimmun. 2018;88:91\u2013102.","journal-title":"J Autoimmun"},{"key":"4246_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2021.03.019","author":"CY Chan","year":"2021","unstructured":"Chan CY, Teo S, Lu L, Chan YH, Lau PY, Than M, et al. Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy. Transl Res. 2021. https:\/\/doi.org\/10.1016\/j.trsl.2021.03.019.","journal-title":"Transl Res"},{"key":"4246_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s10157-023-02343-z","volume":"27","author":"T Kanamori","year":"2023","unstructured":"Kanamori T, Kamei K, Sato M, Nishi K, Okutsu M, Ishiwa S, et al. CD4\u2009+\u2009and CD8\u2009+\u2009T-lymphocyte number as predictive marker of relapse after rituximab treatment in childhood-onset refractory nephrotic syndrome. Clin Exp Nephrol. 2023;27:622\u201330.","journal-title":"Clin Exp Nephrol"},{"key":"4246_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s10157-017-1415-8","volume":"22","author":"M Sato","year":"2018","unstructured":"Sato M, Kamei K, Ogura M, Ishikura K, Ito S. Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion. Clin Exp Nephrol. 2018;22:110\u20136.","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"4246_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00467-024-06570-8","volume":"40","author":"EY Chan","year":"2025","unstructured":"Chan EY, Lin KY, Yap DY, et al. Obinutuzumab as a viable therapeutic strategy in rituximab-refractory childhood frequently relapsing, steroid-dependent nephrotic syndrome that relapsed during B-cell depletion. Pediatr Nephrol. 2025;40(3):711\u20134.","journal-title":"Pediatr Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04246-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04246-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04246-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T23:04:54Z","timestamp":1757286294000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04246-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4246"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04246-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the Ethics Committee of the Children\u2019s Hospital Affiliated to the Capital Institute of Pediatrics, approval number SHERLL2022059. Informed consent to participate was obtained from the parents or legal guardians of any participant under the age of 16. Also, we confirmed all the methods included in this study are in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"412"}}